Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 14/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29802559 | 1.00 | KCNH2 (0.55) | KCNH2PTGS2PTGS1MAP4K4PIK3CA | |
| SCHEMBL23093455 | 0.80 | KCNH2 (0.47) | KCNH2PTGS2PTGS1 | |
| SCHEMBL23110694 | 0.77 | SYK (0.35) | KCNH2PTGS2PTGS1 | |
| SCHEMBL23093302 | 0.75 | ATR (0.44) | KCNH2PTGS2 | |
| SCHEMBL28178962 | 0.74 | KCNH2 (0.68) | KCNH2PTGS2PTGS1MAP4K4PIK3CA | |
| SCHEMBL28178965 | 0.72 | PTGS2 (0.56) | KCNH2PTGS2PTGS1 | |
| SCHEMBL15306535 | 0.71 | KCNH2 (0.48) | KCNH2PTGS2PTGS1 | |
| SCHEMBL3489890 | 0.71 | NR1H2 (0.53) | KCNH2PTGS2PTGS1 | |
| SCHEMBL15201323 | 0.71 | KCNH2 (0.78) | KCNH2PTGS2MAP4K4PIK3CAMINK1 | |
| SCHEMBL15201275 | 0.71 | KCNH2 (1.00) | KCNH2PTGS2MAP4K4PIK3CAMINK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220348590-A1 | CYCLOOXYGENASE-2 INHIBITORS AND USES THEREOF | THE BOARD INSTITUTE, INC. (US) | 2022-11-03 | — | — | US | disclosed |
| EP-4027993-A1 | CYCLOOXYGENASE-2 INHIBITORS AND USES THEREOF | The Broad Institute Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| WO-2021050700-A1 | CYCLOOXYGENASE-2 INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021050700-A1 | CYCLOOXYGENASE-2 INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348590-A1 | CYCLOOXYGENASE-2 INHIBITORS AND USES THEREOF | PTGES2, PTGS2, PTGES | KCNH2 3964/4885PTGS2 2/4885PTGS1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.